

Joel Raskin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10733184/publications.pdf>

Version: 2024-02-01

40
papers

3,147
citations

201385

27
h-index

288905

40
g-index

40
all docs

40
docs citations

40
times ranked

3637
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term safety and efficacy of lasmiditan for acute treatment of migraine: Final results of the GLADIATOR study. <i>Cephalalgia Reports</i> , 2020, 3, 251581632095817.	0.2	8
2	Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). <i>Cephalalgia</i> , 2019, 39, 1343-1357.	1.8	66
3	On the path to 2025: understanding the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 60.	3.0	316
4	Drug development in Alzheimer's disease: the path to 2025. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 39.	3.0	323
5	Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 205-214.	1.2	57
6	Neurobiology of Alzheimer's Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions. <i>Current Alzheimer Research</i> , 2015, 12, 712-722.	0.7	134
7	Acute and Long-term Treatment of Late-Life Major Depressive Disorder: Duloxetine Versus Placebo. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 34-45.	0.6	52
8	Cognitive and Functional Decline and Their Relationship in Patients with Mild Alzheimer's Dementia. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 949-955.	1.2	63
9	The relationship between change in apathy and changes in cognition and functional outcomes in currently non-depressed SSRI-treated patients with major depressive disorder. <i>Comprehensive Psychiatry</i> , 2014, 55, 1-10.	1.5	55
10	Safety and tolerability of duloxetine in elderly patients with major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2013, 28, 1-11.	0.9	12
11	Assessment of Falls in Older Patients Treated With Duloxetine. <i>primary care companion for CNS disorders, The</i> , 2013, 15, .	0.2	2
12	Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: Outcomes following randomized switch to either duloxetine or escitalopram. <i>Journal of Psychiatric Research</i> , 2012, 46, 667-674.	1.5	21
13	The Effect of Initial Duloxetine Dosing Strategy on Nausea in Korean Patients with Major Depressive Disorder. <i>Psychiatry Investigation</i> , 2012, 9, 391.	0.7	4
14	Clinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetine. <i>Human Psychopharmacology</i> , 2011, 26, 242-251.	0.7	11
15	Meta-analyses and antidepressant prescribing. <i>Journal of Psychopharmacology</i> , 2010, 24, 629-630.	2.0	1
16	Safety and Efficacy of Duloxetine in the Treatment of Diabetic Peripheral Neuropathic Pain in Older Patients. <i>Current Drug Safety</i> , 2009, 4, 22-29.	0.3	32
17	Duloxetine for the Treatment of Recurrent Major Depressive Disorder in Elderly Patients: Treatment Outcomes in Patients With Comorbid Arthritis. <i>Psychosomatics</i> , 2009, 50, 402-412.	2.5	25
18	Association between Painful Physical Symptoms and Clinical Outcomes in Korean Patients with Major Depressive Disorder: A Three-Month Observational Study. <i>Psychiatry Investigation</i> , 2009, 6, 255.	0.7	12

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. <i>Depression and Anxiety</i> , 2008, 25, 182-189.	2.0	146
20	Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies. <i>Human Psychopharmacology</i> , 2008, 23, 519-526.	0.7	45
21	A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. <i>Journal of Psychiatric Research</i> , 2008, 42, 22-34.	1.5	63
22	Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder. <i>International Psychogeriatrics</i> , 2008, 20, 309-27.	0.6	25
23	Safety and Tolerability of Duloxetine at 60 mg Once Daily in Elderly Patients With Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 32-38.	0.7	45
24	Efficacy of Duloxetine on Cognition, Depression, and Pain in Elderly Patients With Major Depressive Disorder: An 8-Week, Double-Blind, Placebo-Controlled Trial. <i>American Journal of Psychiatry</i> , 2007, 164, 900-909.	4.0	275
25	Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression. <i>International Clinical Psychopharmacology</i> , 2007, 22, 348-355.	0.9	32
26	An Evaluation of the Cardiovascular Safety Profile of Duloxetine. <i>Drug Safety</i> , 2007, 30, 437-455.	1.4	116
27	Once-daily duloxetine 60 mg in the treatment of major depressive disorder: Multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil. <i>Psychiatry and Clinical Neurosciences</i> , 2007, 61, 295-307.	1.0	44
28	An Open-Label 52-Week Clinical Extension Comparing Duloxetine with Routine Care in Patients with Diabetic Peripheral Neuropathic Pain. <i>Pain Medicine</i> , 2007, 8, 503-513.	0.9	43
29	Duloxetine Treatment for Role Functioning Improvement in Generalized Anxiety Disorder. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 518-524.	1.1	36
30	Efficacy and Safety of Duloxetine 60 mg Once Daily in the Treatment of Pain in Patients With Major Depressive Disorder and At Least Moderate Pain of Unknown Etiology. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1707-1716.	1.1	75
31	Efficacy and tolerability of duloxetine treatment in elderly patients with major depressive disorder and concurrent anxiety symptoms. <i>Psychiatry</i> , 2007, 4, 33-45.	0.3	5
32	Duloxetine versus Routine Care in the Long-Term Management of Diabetic Peripheral Neuropathic Pain. <i>Journal of Palliative Medicine</i> , 2006, 9, 29-40.	0.6	105
33	Duloxetine in the long-term management of diabetic peripheral neuropathic pain: An open-label, 52-week extension of a randomized controlled clinical trial. <i>Current Therapeutic Research</i> , 2006, 67, 283-304.	0.5	23
34	Duloxetine in the treatment of major depressive disorder: an assessment of the relationship between outcomes and episode characteristics. <i>International Clinical Psychopharmacology</i> , 2006, 21, 285-295.	0.9	11
35	Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?. <i>International Clinical Psychopharmacology</i> , 2006, 21, 311-317.	0.9	76
36	Duloxetine for Patients with Diabetic Peripheral Neuropathic Pain: A 6-Month Open-Label Safety Study. <i>Pain Medicine</i> , 2006, 7, 373-385.	0.9	78

#	ARTICLE	IF	CITATIONS
37	A Double-Blind, Randomized Multicenter Trial Comparing Duloxetine with Placebo in the Management of Diabetic Peripheral Neuropathic Pain. <i>Pain Medicine</i> , 2005, 6, 346-356.	0.9	503
38	Duloxetine in the treatment of Major Depressive Disorder: A comparison of efficacy in patients with and without melancholic features. <i>BMC Psychiatry</i> , 2005, 5, 1.	1.1	54
39	Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. <i>Clinical Therapeutics</i> , 2004, 26, 1446-1455.	1.1	59
40	Duloxetine in the Long-Term Treatment of Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 1237-1244.	1.1	94